TopicalDosed ingredientTherapeutic flag Cosmetic cross-reference

Cysteamine Hydrochloride

CAS 156-57-0

Cysteamine Hydrochloride (CAS 156-57-0) is a Phase 4 pharmaceutical compound with 2 bioactivity targets and 22 adverse event associations.

SOURCE NLM DailyMed
Label records
0
SOURCE EMBL-EBI ChEMBL
Bioactivity
2
SOURCE DrugCentral
Adverse signals
22
SOURCE IUPHAR/BPS
PubMed IDs
0
SOURCE EMBL-EBI ChEMBL B25820EEF0F0

Compound Identity

Matched identifiers and naming fields for the pharmaceutical compound record.

Primary Name
Cysteamine Hydrochloride
CAS Number
156-57-0
UNII
IF1B771SVB
InChIKey
OGMADIBCHLQMIP-UHFFFAOYSA-N
ChEMBL ID
CHEMBL1256137
Molecule Type
Small molecule
Source Match
EMBL-EBI ChEMBL (INCHIKEY)
dosed ingredienttherapeutic flagtopical
SOURCE EMBL-EBI ChEMBL B25820EEF0F0

Clinical Development Phase

Highest clinical development phase rendered from the matched compound identifier rows.

Phase 4 (Approved)
Approved or marketed human pharmaceutical use is represented in the source phase field.
ChEMBL CHEMBL1256137 | Small molecule
SOURCE Ingredients table / CosIng profile same-CAS cross-reference

Cross-Reference to Cosmetics

Same-CAS ingredient record found in the cosmetics vertical.

This substance also has a cosmetic safety profile →
SOURCE EMBL-EBI ChEMBL 2 bioactivity rows

Bioactivity & Target Interactions

Target-level activity records with assay counts, activity type, and measured value where present.

TargetActivity ValueAssaysOrganism
- GI50 98996.55907407409 nM 54 -
- Potency 21032.765714285717 nM 23 -
SOURCE NLM RxNorm 2 name rows

Drug Names / RxNorm

Normalized drug-name vocabulary rows, RxCUIs, and source abbreviations.

NameRxCUI TypeSource
CYSTEAMINE HYDROCHLORIDE 1426886 SU MTHSPL
cysteamine hydrochloride 1426886 PIN RXNORM
SOURCE Rendered pharma page rows FAQPage JSON-LD

Frequently Asked Questions

Short answers generated only from the same visible source-linked rows on this page.

What is Cysteamine Hydrochloride used for in pharmaceutical contexts?

Cysteamine Hydrochloride (CAS 156-57-0) is rendered as a pharmaceutical compound from the matched source rows; no DailyMed product-name rows are present in this page query.

What are the known adverse events for Cysteamine Hydrochloride?

Cysteamine Hydrochloride has 22 DrugCentral/FAERS adverse event associations. Rendered reaction terms include Abnormal sensation in eye, Amino acid level increased, Corneal degeneration, Corneal neovascularisation, Death. Signal rows are source-linked records and should not be read as incidence rates or causality conclusions.

Is Cysteamine Hydrochloride also used in cosmetics?

Yes. The ingredients table has a same-CAS cosmetic profile for Cysteamine HCl with EU status "restricted".

What clinical phase is Cysteamine Hydrochloride in?

Cysteamine Hydrochloride is rendered with ChEMBL max phase 4 (approved).